Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 20,943 | 37,354 | 56,221 | 29,498 | 81,501 |
| Marketable Securities | 27,174 | 28,514 | 44,556 | 67,225 | 31,048 |
| Receivables | 15,505 | 12,493 | 12,704 | 9,429 | 11,595 |
| Inventories | 4,988 | 5,466 | 4,325 | 4,862 | 5,047 |
| TOTAL | $81,333 | $95,973 | $128,907 | $121,594 | $139,624 |
| Non-Current Assets | |||||
| PPE Net | 910 | 1,103 | 1,297 | 1,519 | 1,605 |
| Investments And Advances | 7,970 | 10,165 | 0 | 0 | 673 |
| Other Non-Current Assets | 5,148 | 5,713 | 5,415 | 5,360 | 4,239 |
| TOTAL | $14,028 | $16,981 | $6,712 | $6,879 | $6,517 |
| Total Assets | $95,361 | $112,954 | $135,619 | $128,473 | $146,141 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,403 | 17,130 | 12,383 | 9,356 | 8,647 |
| Accrued Expenses | 6,721 | 4,919 | 8,257 | 6,625 | 6,428 |
| Other current liabilities | 3,641 | 3,185 | 3,276 | 3,018 | 2,965 |
| TOTAL | $26,765 | $25,234 | $23,916 | $18,999 | $18,040 |
| Non-Current Liabilities | |||||
| Long Term Debt | 98,296 | 97,941 | 97,537 | 71,870 | 71,196 |
| Other Non-Current Liabilities | 108,734 | 106,333 | 103,527 | 100,890 | 97,818 |
| TOTAL | $207,030 | $204,274 | $201,064 | $172,760 | $169,014 |
| Total Liabilities | $233,795 | $229,508 | $224,980 | $191,759 | $187,054 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,283 | 23,454 | 23,441 | 23,090 | 22,741 |
| Common Shares | 64 | 64 | 63 | 63 | 62 |
| Retained earnings | -631,453 | -607,317 | -577,104 | -548,235 | -522,404 |
| Other shareholders' equity | -154 | -45 | -107 | -155 | -56 |
| TOTAL | $-138,434 | $-116,554 | $-89,361 | $-63,286 | $-40,913 |
| Total Liabilities And Equity | $95,361 | $112,954 | $135,619 | $128,473 | $146,141 |